Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
New Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
Download Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzRedipred – Data Sheet Page 3 of 11 dosage appear to be important factors in determining suppression of the pituitary adrenal axis and response to stress on cessation of steroid treatment.
Related documents
Mixing Insulins: 10 Units of Regular and 20 Units of …
wps.prenhall.com490 UNIT IV / Responses to Altered Endocrine Function Lipodystrophy. Lipodystrophy (hypertrophy of subcuta-neous tissue) or lipoatrophy (atrophy of subcutaneous tissue) may result if the same injection sites are used repeatedly, espe-
Insulin Administration - Diabetes Care
care.diabetesjournals.orgInsulin Administration AMERICAN DIABETES ASSOCIATION I nsulinisnecessaryfornormalcarbohy-drate, protein, and fat metabolism. Peoplewithtype1diabetesmellitusdo not produce enough of this hormone to
Getting started - Home | Diabetes Canada
www.diabetes.caInsulin Pens: Your pen comes with an instruction book. Please review it to understand how your pen works, how to load the cartridge, and how to prepare your pen for an
Insulin Pen Start Checklist Help Sheet - Diabetes …
www.diabetes.caPremixed insulins Premixed regular insulin • Humulin 30/70 / Novolin ge 30/70, 40/60, 50/50 Varies according to types of insulin contains a fixed ratio of
How to Switch Between Insulin Products - …
www.mysccg.comDetail-Document #251005 − This Detail-Document accompanies the related article published in − PHARMACIST’S LETTER / PRESCRIBER’S LETTER October 2009 ~ Volume 25 ~ Number 251005